AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26850805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25628416 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR/Amlodipine
Number of subjects: 291
Study 25628416 — intervention group
Group type: COMPARATOR
Intervention: Enalapril/Amlodipine
Number of subjects: 291
Study 25628416 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR/Amlodipine (Amlodipine 10 mg subgroup)
Number of subjects: 291
Study 25628416 — intervention group
Group type: COMPARATOR
Intervention: Enalapril/Amlodipine (Amlodipine 10 mg subgroup)
Number of subjects: 291
Study 24124708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rFVIIa (20 µg/kg)
Number of subjects: 86
Study 24124708 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 86
Study 21905967 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus Amlodipine 10 mg
Number of subjects: 0
Study 21905967 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg plus Amlodipine 10 mg
Number of subjects: 0
Study 21905967 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus Amlodipine combinations
Number of subjects: 0
Study 17588688 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 gr/d)
Number of subjects: 10
Study 17588688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16536651 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 16536651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15454860 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of nicorandil (1.0 microg.kg(‐1).min(‐1))
Number of subjects: 24
Study 15454860 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 24
Study 11207038 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Cisplatin 20 mg/m(2) i.v. per day for 4 days, followed by Cy 2 g/m(2) i.v. on day 4; 12 partial responses (PR), 1 mixed response, 3 stable disease (SD).
Number of subjects: 21
Study 11207038 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Basic chemotherapy plus VP16 (50 mg/m(2) i.v. for 3 days) and Vincristine (1.5 mg/m(2) i.v. on days 1 and 6); 2 PR, 1 complete response (CR), and 2 very good partial responses (VGPR) in 5 patients treated at diagnosis.
Number of subjects: 21
Study 11207038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (CO-TH) with 131-I-MIBG (200 mCi) administered on day 10 after chemotherapy; no extra-medullary toxicity observed, mild myelosuppression in patients treated at diagnosis.
Number of subjects: 21
Study 9398455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (oral)
Number of subjects: 24
Study 7991476 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (tissue plasminogen activator combined with intravenous heparin)
Number of subjects: 0
Study 7991476 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated administration of tissue plasminogen activator (Activase) combined with intravenous heparin
Number of subjects: 0
Study 7991476 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 3283460 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH arterial lactate concentrations (perioperative infusion of Ringer's lactate)
Number of subjects: 19
Study 3283460 — intervention group
Group type: COMPARATOR
Intervention: LOW arterial lactate concentrations (no exogenous lactate)
Number of subjects: 19
Study 3283460 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH arterial lactate concentrations
Number of subjects: 19
Study 30257663 — intervention group
Group type: EXPERIMENTAL
Intervention: We Act - Together for Health intervention
Number of subjects: 548
Study 26678956 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 3047
Study 26678956 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3047
Study 26678956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3047
Study 26678956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3047
Study 24331152 — intervention group
Group type: EXPERIMENTAL
Intervention: 180‐W GL XPS
Number of subjects: 281
Study 24331152 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 281
Study 22101205 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus cognitive behavioural therapy (CBT)
Number of subjects: 0
Study 22101205 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 20100633 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium miniplates
Number of subjects: 40
Study 20100633 — intervention group
Group type: COMPARATOR
Intervention: Bioresorbable miniplates
Number of subjects: 40
Study 18757660 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multiple risk intervention delivered mainly during pregnancy
Number of subjects: 0
Study 18757660 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16401159 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 99
Study 16401159 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 99
Study 14713659 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural-language search queries
Number of subjects: 7500
Study 10754919 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 30
Study 10754919 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 30
Study 10754919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8696720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Number of subjects: 0
Study 8696720 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide combination therapy
Number of subjects: 0
Study 2071959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 0.5 g (0.5 g twice a day for 14 days)
Number of subjects: 470
Study 2071959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 1.0 g (1.0 g twice a day for 14 days)
Number of subjects: 470
Study 2071959 — intervention group
Group type: COMPARATOR
Intervention: CAZ (1.0 g twice a day for 14 days)
Number of subjects: 470
Study 2071959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 0.5 g (in patients with pneumonia)
Number of subjects: 470
Study 2071959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 1.0 g (in patients with pneumonia)
Number of subjects: 470
Study 2071959 — intervention group
Group type: COMPARATOR
Intervention: CAZ (in patients with pneumonia)
Number of subjects: 470
Study 2071959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 0.5 g (in patients with chronic respiratory tract infection)
Number of subjects: 470
Study 2071959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 1.0 g (in patients with chronic respiratory tract infection)
Number of subjects: 470
Study 2071959 — intervention group
Group type: COMPARATOR
Intervention: CAZ (in patients with chronic respiratory tract infection)
Number of subjects: 470
Study 6140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled catheters
Number of subjects: 99
Study 6140494 — intervention group
Group type: COMPARATOR
Intervention: Untunnelled catheters
Number of subjects: 99
Study 6140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition nurse intervention
Number of subjects: 99
Study 6140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent internal sepsis
Number of subjects: 99
Study 31208475 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour cream
Number of subjects: 47
Study 31208475 — intervention group
Group type: COMPARATOR
Intervention: Butter, cheese, whipped cream, sour cream
Number of subjects: 47
Study 29364754 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocervical flexion exercise (CFE), 30 minutes/day, 3 times a week for 8 weeks
Number of subjects: 41
Study 29364754 — intervention group
Group type: COMPARATOR
Intervention: Isometric neck exercise (NIE), 30 minutes/day, 3 times a week for 8 weeks
Number of subjects: 41
Study 26940483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination message focused on benefits to society
Number of subjects: 495
Study 26940483 — intervention group
Group type: COMPARATOR
Intervention: Vaccination message focused on benefits to self
Number of subjects: 495
Study 26940483 — intervention group
Group type: COMPARATOR
Intervention: Vaccination message focused on benefits to loved ones
Number of subjects: 495
Study 28065217 — intervention group
Group type: EXPERIMENTAL
Intervention: EN+PN
Number of subjects: 120
Study 28065217 — intervention group
Group type: COMPARATOR
Intervention: EN
Number of subjects: 120
Study 23312052 — intervention group
Group type: EXPERIMENTAL
Intervention: IPE 4 g/day
Number of subjects: 229
Study 23312052 — intervention group
Group type: COMPARATOR
Intervention: IPE 2 g/day
Number of subjects: 229
Study 23312052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 19695922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glycididazole (700 mg/m² intravenous infusion 30 minutes before radiotherapy three times a week)
Number of subjects: 60
Study 19695922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium glycididazole)
Number of subjects: 60
Study 19695922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glycididazole
Number of subjects: 60
Study 18554699 — intervention group
Group type: EXPERIMENTAL
Intervention: squeeze (n = 72)
Number of subjects: 151
Study 18554699 — intervention group
Group type: COMPARATOR
Intervention: no squeeze (n = 79)
Number of subjects: 151
Study 16038820 — intervention group
Group type: EXPERIMENTAL
Intervention: MVB (mesenteric vein bioprosthesis)
Number of subjects: 276
Study 16038820 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic grafts
Number of subjects: 276
Study 16038820 — intervention group
Group type: COMPARATOR
Intervention: INT (historic control group)
Number of subjects: 276
Study 12439665 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbscan
Number of subjects: 39
Study 12439665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Pachymetry
Number of subjects: 39
Study 12439665 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 39
Study 12439665 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT (after correction factor applied)
Number of subjects: 39
Study 10329031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 277
Study 10329031 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (NFT)
Number of subjects: 277
Study 8602778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 291
Study 1669033 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI + LT3 (clomipramine 150 mg/day + LT3 50 micrograms/day)
Number of subjects: 20
Study 1669033 — intervention group
Group type: COMPARATOR
Intervention: CMI + placebo (clomipramine 150 mg/day)
Number of subjects: 20
Study 6365008 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole troches (10 mg) three times a day
Number of subjects: 84
Study 6365008 — intervention group
Group type: COMPARATOR
Intervention: Placebo troches
Number of subjects: 84
Study 30169855 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EP)
Number of subjects: 4
Study 30169855 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 4
Study 26762528 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine without human serum albumin (HSA)
Number of subjects: 244
Study 26762528 — intervention group
Group type: COMPARATOR
Intervention: Licensed varicella vaccine containing HSA
Number of subjects: 244
Study 26762528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 244
Study 24485327 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental smartphone application
Number of subjects: 134
Study 24485327 — intervention group
Group type: COMPARATOR
Intervention: W82GO Healthy Lifestyles intervention (usual care)
Number of subjects: 134
Study 22332671 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (75 J cm(‐2) red light)
Number of subjects: 20
Study 22332671 — intervention group
Group type: COMPARATOR
Intervention: Control area (chemical keratolytic treatment)
Number of subjects: 20
Study 20382963 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention in prevalent CKD patients
Number of subjects: 0
Study 20382963 — intervention group
Group type: COMPARATOR
Intervention: Treatment centre
Number of subjects: 0
Study 20382963 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for progression of kidney failure and cardiovascular events
Number of subjects: 0
Study 22379913 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 38
Study 22379913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22379913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 38
Study 22379913 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Lornoxicam
Number of subjects: 38
Study 16046230 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide suspension
Number of subjects: 0
Study 16046230 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-containing toothpaste
Number of subjects: 0
Study 16046230 — intervention group
Group type: COMPARATOR
Intervention: Zinc-free toothpaste
Number of subjects: 0
Study 11809159 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory oddball paradigm with button-press response
Number of subjects: 11
Study 9510982 — intervention group
Group type: EXPERIMENTAL
Intervention: Josacine 500 mg tablets (2 tablets)
Number of subjects: 6
Study 9510982 — intervention group
Group type: COMPARATOR
Intervention: Josamycin solution (1 g drug, buffered at pH 4.0)
Number of subjects: 6
Study 7985598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol therapy
Number of subjects: 0
Study 7985598 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 7985598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 0
Study 2686453 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives
Number of subjects: 0
Study 2686453 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30533392 — intervention group
Group type: EXPERIMENTAL
Intervention: On-table extubation (OTE) group with sufentanil 0.15 µg/kg/h
Number of subjects: 100
Study 30533392 — intervention group
Group type: COMPARATOR
Intervention: Control group with sufentanil 0.7-0.8 µg/kg/h
Number of subjects: 100
Study 30533392 — intervention group
Group type: EXPERIMENTAL
Intervention: On-table extubation (OTE) group
Number of subjects: 100
Study 30533392 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 28298261 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 10mg/day
Number of subjects: 412
Study 28298261 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25mg/day
Number of subjects: 412
Study 28298261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 25739769 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing rapid diagnostic tests with realistic training
Number of subjects: 4603
Study 25739769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rapid diagnostic tests)
Number of subjects: 4603
Study 23850055 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1452
Study 23850055 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1452
Study 23850055 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1452
Study 23850055 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 1452
Study 20885970 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole (2 g, once)
Number of subjects: 577
Study 20885970 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (500 mg, b.i.d for seven days)
Number of subjects: 577
Study 18978097 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm and lubricant gel provision
Number of subjects: 2040
Study 18978097 — intervention group
Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 2040
Study 16357549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 58
Study 16357549 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 58
Study 12954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging external fixation
Number of subjects: 85
Study 12954250 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization
Number of subjects: 85
Study 12813842 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to screening sigmoidoscopy with explanatory leaflet
Number of subjects: 0
Study 12813842 — intervention group
Group type: COMPARATOR
Intervention: Invitation to screening sigmoidoscopy with explanatory leaflet and option to discuss with general practitioner
Number of subjects: 0
Study 8871834 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 2 3.10(6) MU/3 times/week
Number of subjects: 20
Study 8871834 — intervention group
Group type: COMPARATOR
Intervention: OH-chloroquine (OH-C) 6 mg/kg/daily
Number of subjects: 20
Study 1613201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Pressure Release Ventilation (IMPRV)
Number of subjects: 16
Study 6144316 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 42 min)
Number of subjects: 36
Study 6144316 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 12 min)
Number of subjects: 36
Study 6144316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of vecuronium (loading dose 0.075 mg kg‐1, continuous infusion 0.075 mg kg‐1 h‐1)
Number of subjects: 36
Study 31474280 — intervention group
Group type: EXPERIMENTAL
Intervention: Belonging intervention (brief reading-writing exercise)
Number of subjects: 86
Study 31474280 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 86
Study 26152558 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist smoking cessation services
Number of subjects: 1404
Study 26152558 — intervention group
Group type: COMPARATOR
Intervention: Nonspecialist smoking cessation services
Number of subjects: 1404
Study 25113425 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril (Group R; n = 96)
Number of subjects: 191
Study 25113425 — intervention group
Group type: COMPARATOR
Intervention: Left nostril (Group L; n = 95)
Number of subjects: 191
Study 22189698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 32
Study 22189698 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 32
Study 22718435 — intervention group
Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 306
Study 22718435 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 306
Study 22718435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline + Rifampin
Number of subjects: 306
Study 22718435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 18031501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream
Number of subjects: 36
Study 18031501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 36
Study 18031501 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 36
Study 18031501 — intervention group
Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 36
Study 18031501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream and 1% hydrocortisone cream
Number of subjects: 36
Study 15976800 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) infusion
Number of subjects: 940
Study 15976800 — intervention group
Group type: COMPARATOR
Intervention: No GIK (Control)
Number of subjects: 940
Study 15976800 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 940
Study 15976800 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 940
Study 15976800 — intervention group
Group type: COMPARATOR
Intervention: GIK and Control
Number of subjects: 940
Study 12469639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical immunotherapy with imuron (6-week course) and maintenance therapy (3 weekly instillations each 3 months for the first year followed by once in 6 months)
Number of subjects: 62
Study 12469639 — intervention group
Group type: COMPARATOR
Intervention: Single monthly instillations
Number of subjects: 62
Study 12469639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG-therapy
Number of subjects: 62
Study 12469639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever as a side effect
Number of subjects: 62
Study 9804564 — intervention group
Group type: EXPERIMENTAL
Intervention: Subatmospheric pressure environment (‐30 to ‐40 mmHg) with heat (45‐46 degreesC, water‐perfused blanket) applied to a single forearm and hand.
Number of subjects: 16
Study 9804564 — intervention group
Group type: COMPARATOR
Intervention: Heat alone applied to control subjects.
Number of subjects: 16
Study 7614099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine 0.5 g daily
Number of subjects: 162
Study 7614099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine 1.25 g daily
Number of subjects: 162
Study 7614099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine 2.0 g daily
Number of subjects: 162
Study 7614099 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine 2.0 g daily
Number of subjects: 162
Study 7614099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (all doses)
Number of subjects: 162
Study 2615532 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nystatin (NYS), pipemidic acid (PPA), and colistin sodium methanesulfonate (CLM)
Number of subjects: 29
Study 2615532 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (NYS) alone
Number of subjects: 29